Drug Retail

Huaren Health

Huaren Health released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 1.421 B, actual EPS CNY 0.1984

Huaren Health released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 1.594 B, actual EPS CNY 0.0877

Huaren Health released FY2025 earnings on April 24 After-Market (BJT), actual revenue CNY 5.487 B, actual EPS CNY 0.48

Huaren Health to Release FY2026 Q1 Earnings on April 25 After-Market (BJT)

Huaren Health to Release FY2025 Earnings on April 25 After-Market (BJT)

Huaren Health released FY2025 9 Months Earnings on October 24 After-Market (BJT), Actual Revenue CNY 3.892 B, Actual EPS CNY 0.3918

Huaren Health released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 1.389B, actual EPS CNY 0.1323

Huaren Health FY2025 Q3 Earnings Release on October 25 After-Market BJT

Huaren Health released FY2025 Semi-Annual earnings on August 26 Pre-Market (BJT), actual revenue CNY 2.504 B, actual EPS CNY 0.2594

Huaren Health released FY2025 Q2 earnings on August 26 Pre-Market (BJT), actual revenue CNY 1.237 B, actual EPS CNY 0.1063

Huaren Health to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Anhui Huaren Health Medicine Submits New Trademark Application with Increased R&D Investment

Anhui Chinese Health Pharmaceutical Co., Ltd. Submits New Trademark Registration Applications and Increases R&D Investment

Huaren Health Completes Acquisition of Three Pharmaceutical Chain Companies

Huaren Health Plans to Acquire Shares of Multiple Companies

Anhui Chinese Health Pharmaceutical Co., Ltd. Applies for a New Trademark Registration for 'Gonenjian'

Huaren Health's Q1 Operating Cash Flow Net Increase by 130%

Huaren Health's net profit grew by 28.15% in Q1 2025

Huaren Health released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 1.267 B, actual EPS CNY 0.1531

Huaren Health Reports 19.34% Revenue Growth in 2024

301017

600488

301584

000788

301408

600594

603222

600829

301015

603122

China's A-share pharmaceutical industry chain continues to strengthen, with Chimin and CMC hitting the daily limit, following TJPC, YIBAI PHARMACEUTICAL, and PKU HEALTHCARE also hitting the daily limit. Previously, Huaren Health, Baheal Medical, SYPM, INNOSTIC, and HRPC, among other stocks, rose more than 5%

Wallstreetcn

SYPM

TJPC

C&D INNOSTIC

PKU HEALTHCARE

YIBAI PHARMACEUTICAL

Chimin

HRPC

Baheal Medical

According to the Zhitong Finance APP, Huaren Health released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 3.892 billion yuan, a year-on-year increase of 19.06%. The net profit attributable to shareholders of the listed company was 157 million yuan, a year-on-year increase of 45.21%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 151 million yuan, a year-on-year increase of 51.00%. The basic earnings per share were 0.3918 yuan

Zhitong

Huaren Health released its performance for the first three quarters, with a net profit attributable to the parent company of 157 million yuan, an increase of 45.21%

Huaren Health's wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application for Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration. This new drug is a potassium ion competitive acid blocker that can effectively inhibit gastric acid secretion without relying on an acidic environment, significantly reducing the occurrence of nighttime gastric acid elevation

Huaren Health: The application for the registration and marketing authorization of Furmaric Acid Voronol Tablets has been accepted

Huaren Health recently stated during an institutional research meeting that the company's management, based on strategic layout, prefers to adopt a prudent integration strategy: on one hand, focusing on developing chain franchise businesses; on the other hand, strengthening regional markets through small-scale acquisitions in already entered markets, rather than large-scale expansion. In the short term, the company will adopt a cautious approach to seize integration opportunities and continue to monitor market dynamics

Huaren Health: The company prefers a prudent integration strategy rather than large-scale expansion

According to the Zhitong Finance APP, Huaren Health released its semi-annual report for 2025, with operating revenue of 2.504 billion yuan, a year-on-year increase of 15.52%. The net profit attributable to shareholders of the listed company was 104 million yuan, a year-on-year increase of 42.17%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 101 million yuan, a year-on-year increase of 43.28%. The basic earnings per share were 0.2594 yuan

Huaren Health released its performance for the first half of the year, with a net profit attributable to the parent company of 104 million yuan, an increase of 42.17%

300253

SPD concept stocks surged, Huaren Health hit the daily limit up of 20%, Winning Health rose over 10%, Chuangye Huikang and SYPM rose over 5%

Winning Health

Huaren Health plans to acquire equity in three pharmaceutical chain companies in Fujian and Zhejiang for a total price of 328 million yuan, advancing its pharmaceutical retail business development. This acquisition will enhance the company's market share and brand influence in the East China region, and upon completion, it will control Yangzu Huimin, Haihua Pharmaceutical, and Tonglu Yishengtang, marking the company's transformation from a local enterprise to a regional pharmaceutical chain enterprise

Huaren Health plans to acquire equity in three pharmaceutical chain companies in Fujian and Zhejiang to advance its pharmaceutical retail business

Huaren Health announced that the company plans to purchase a 46.01% equity stake in Yangzu Huimin for RMB 133 million, a 46.01% equity stake in Haihua Pharmaceutical for RMB 125 million, and a 70.01% equity stake in Tonglu Yishengtang for RMB 68.2598 million. Upon completion of this transaction, the target companies will be included in the company's consolidated financial statements. The company plans to use its own funds and change part of the fundraising purposes for payment. If the review for changing the fundraising purposes is not approved, all payments will be made using its own funds

Huaren Health: Plans to acquire 46.01% equity of Yangzu Huimin for 133 million yuan

300937

605266

002727

Pharmaceutical commercial stocks opened strong, with YIXINTANG hitting the limit up, Hezong Medicine Easy-To-Buy Pharmaceutical rising over 10%, and JZJ, Saili Medical, Huaren Health, SYPM, and others following suit

Hezong Medicine Easy-To-Buy Pharmaceutical

YIXINTANG

Thalys

Huaren Health(301408.SZ)